INTERFERENCE A JOURNAL OF AUDIO CULTURE · Jul 16, 2026
GLP-1 agonist-based therapy versus basal insulin in older adults with type 2 diabetes mellitus: implications for glycemic control and clinical outcomes
By Neto JCDALC, Gomes LRDL, dos Santos ACC et al.
The objective of this study was to compare the efficacy of GLP-1 receptor agonists (liraglutide, semaglutide, and tirzepatide) versus basal insulin for glycemic control in older adults with type 2 diabetes mellitus (DM2). A systematic literature review was conducted following the PRISMA protocol guidelines, with the protocol registered in PROSPERO (CRD420251104563). The search, conducted between March and April 2025, used six databases and resulted in the inclusion of 15 scientific articles in the final synthesis. The results demonstrated that incretin agonist-based therapy is consistently superior to basal insulin for the control of DM2. Regarding glycemic control, tirzepatide (a dual GIP/GLP-1 agonist) was superior to insulin glargine in the SURPASS-4 study, achieving reductions in glycated hemoglobin (HbA1c) between -2.24% and -2.58%, compared with -1.44% for glargine. In addition, GLP-1 agonists, including liraglutide and semaglutide, promoted significant reductions in body weight, whereas insulin glargine resulted in weight gain. The class of GLP-1 RAs demonstrated a considerably lower risk of clinically significant hypoglycemia (6%–9%) compared with insulin glargine (19%). In the older population (≥65 years), oral semaglutide showed efficacy in reducing HbA1c and weight. However, in very old patients (≥75 years), a higher frequency of discontinuation due to gastrointestinal adverse effects and a potential risk of hypoglycemia were observed. GLP-1 agonists and dual agonists did not increase the risk of major adverse cardiovascular events (MACE-4). It is concluded that GLP-1 agonists and dual incretin agonists are superior to basal insulin in the management of DM2 in older adults, offering better glycemic and metabolic control with a lower risk of hypoglycemia, but requiring careful monitoring in older adults of advanced age (75 years).
doi.org/10.36557/2009-3578.2026v12n2p84-109Open accessInterventions